[Form 4] The Campbell's Company Insider Trading Activity

Rhea-AI Filing Summary

Crinetics Pharmaceuticals, Inc. (CRNX) filed a Form 8-K under Item 7.01 (Regulation FD). The filing discloses that the company issued a press release announcing eight scientific abstracts from its endocrine and rare-disease pipeline that will be presented at the Endocrine Society’s Annual Meeting (ENDO 2025) in San Francisco, July 12-15, 2025.

The abstracts will cover development candidates atumelnant (ACTH antagonist), paltusotine (oral SST2 agonist), and the TSHR antagonist CRN12755. The company also reiterates plans for the potential commercial launch of PALSONIFY (commercial name for paltusotine) if regulatory approval is obtained.

No new clinical data, financial figures, or transaction details are provided in the 8-K; the disclosure is limited to notification of the upcoming presentations. All forward-looking statements are qualified by customary risk factors, including clinical, regulatory, and geopolitical uncertainties.

Positive

• Eight abstracts accepted for ENDO 2025, demonstrating breadth and continued progress across multiple endocrine programs.
• Multiple pipeline candidates highlighted (atumelnant, paltusotine, CRN12755), keeping investor attention on diversified clinical assets.

Negative

• No new clinical or financial data were disclosed, limiting immediate valuation impact.
• Forward-looking statements emphasize numerous development and regulatory risks without providing mitigating updates.

Insights

Biotech Equity Analyst

TL;DR – Pipeline visibility rises, but no new data; limited market impact.

The 8-K merely alerts investors to forthcoming scientific presentations. While announcing eight abstracts does signal an active R&D engine spanning atumelnant, paltusotine, and a TSHR antagonist, the lack of fresh efficacy or safety readouts keeps valuation unchanged for now. Investors will look to ENDO 2025 data for potential inflection points, particularly around paltusotine’s commercial readiness and CRN12755’s first-in-human progress. Absent those results, today’s filing is informational and non-material.

Risk Analyst

TL;DR – Disclosure highlights standard development risks; impact neutral.

The company reiterates numerous forward-looking statements and risk factors common to clinical-stage biopharma: trial timing, regulatory review, supply-chain disruption, and data variability. Because no new commitments or financial obligations arise from the ENDO 2025 participation, downside or upside risk profile is unchanged.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schmidt Kurt

(Last) (First) (Middle)

1 CAMPBELL PLACE

(Street)

CAMDEN NJ 08103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CAMPBELL'S Co [ CPB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Phantom Stock	(1)	06/26/2025		A		2,309.43		(2)	(3)	Common Stock	2,309.43	$0	44,633.8(4)	D

Explanation of Responses:

1. Each share of Phantom Stock is the economic equivalent of one share of issuer common stock.

2. Phantom shares are fully vested.

3. The value of Phantom Stock is payable in cash from the Company's Supplemental Retirement Plan upon reporting person's retirement, resignation or termination.

4. Includes 455.60 shares acquired through dividend reinvestment since the reporting person's last report.

Remarks:

Ex 24 - Power of Attorney

	Marci K. Donnelly, Attorney-in-Fact	06/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

When will Crinetics (CRNX) present its ENDO 2025 abstracts?

The presentations are scheduled for July 12-15, 2025, at the Endocrine Society’s annual meeting in San Francisco.

How many abstracts is Crinetics presenting at ENDO 2025?

The company will present eight abstracts covering several pipeline programs.

Which pipeline programs are included in the ENDO 2025 abstracts?

Abstracts will feature atumelnant, paltusotine, and the TSHR antagonist CRN12755.

Does the 8-K contain new clinical results for paltusotine or atumelnant?

No. The filing only announces upcoming presentations and contains no new efficacy or safety data.

What is PALSONIFY mentioned in the filing?

PALSONIFY is the proposed commercial name for paltusotine, which Crinetics plans to launch if regulatory approval is granted.